Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.41 |
| ▸ | MEN1 | O00255 | 6/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | CRHBP | P24387 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.37 |
| ▸ | THRB | P10828 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1964519 | 1.00 | MAPT (0.41) | MAPTMEN1KMT2ASMN1; SMN2CRHBP | |
| SCHEMBL1960748 | 0.93 | CYP1A2 (0.43) | MAPTMEN1KMT2ASMN1; SMN2CRHBP | |
| SCHEMBL1960749 | 0.93 | CYP1A2 (0.43) | MAPTMEN1KMT2ASMN1; SMN2CRHBP | |
| SCHEMBL1963715 | 0.90 | MAPT (0.43) | MAPTMEN1KMT2ASMN1; SMN2CRHBP | |
| SCHEMBL1963716 | 0.90 | MAPT (0.43) | MAPTMEN1KMT2ASMN1; SMN2CRHBP | |
| SCHEMBL9833537 | 0.85 | MAPT (0.41) | MAPTMEN1KMT2ASMN1; SMN2CRHBP | |
| SCHEMBL11918052 | 0.85 | MAPT (0.41) | MAPTMEN1KMT2ASMN1; SMN2CRHBP | |
| SCHEMBL9834086 | 0.85 | MAPT (0.60) | MAPTMEN1KMT2ASMN1; SMN2CRHBP | |
| SCHEMBL9834091 | 0.85 | MAPT (0.60) | MAPTMEN1KMT2ASMN1; SMN2CRHBP | |
| SCHEMBL1962297 | 0.85 | MEN1 (0.49) | MAPTMEN1KMT2ASMN1; SMN2CRHBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1966158-B1 | SUBSTITUTED CINNOLINE DERIVATIVES AS GABAA-RECEPTOR MODULATORS AND METHOD FOR THEIR SYNTHESIS | ASTRAZENECA AB (SE) | 2012-08-08 | — | — | EP | disclosed |
| US-20110144331-A1 | Cinnoline Compounds for the Treatment of Anxiety, Cognitive and Mood Disorders | ASTRAZENECA AB (SE) | 2011-06-16 | — | — | US | disclosed |
| WO-2010123441-A1 | CRYSTALLINE FORM OF 4-AMINO-8-(2-FLUORO-6-METHOXY-PHENYL)-N-PROPYLCINNOLINE-3- CARBOXAMIDE HYDROGEN SULPHATE, FOR TREATMENT OF ANXIETY DISORDERS | ASTRAZENECA AB (SE) | 2010-10-28 | — | — | WO | disclosed |
| US-20100184738-A1 | Uses of cinnoline compounds to treat schizophrenia | ASTRAZENECA AB (SE) | 2010-07-22 | — | — | US | disclosed |
| US-20090036454-A1 | Compounds and Uses Thereof | ASTRAZENECA AB (SE) | 2009-02-05 | — | — | US | disclosed |
| US-20090018112-A1 | Compounds and Uses Thereof | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | US | disclosed |
| US-20080318925-A1 | Compounds and Uses Thereof - 849 | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| US-7465795-B2 | Compounds and uses thereof | ASTRAZENECA AB (SE) | 2008-12-16 | — | — | US | disclosed |
| US-20070142328-A1 | Compounds and Uses Thereof | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | US | disclosed |
| US-20070142382-A1 | Compounds and Uses Thereof | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142328-A1 | Compounds and Uses Thereof | MAPT, BDNF, PYGB | MAPT 1/4885MEN1 890/4885KMT2A 1551/4885 |
| US-20070142382-A1 | Compounds and Uses Thereof | MAPT, BDNF, PYGB | MAPT 1/4885MEN1 890/4885KMT2A 1551/4885 |
| US-20110144331-A1 | Cinnoline Compounds for the Treatment of Anxiety, Cognitive and Mood Disorders | HTR7, HTR2C, CRH | MAPT 6/4885MEN1 92/4885KMT2A 1653/4885 |
| US-20090018112-A1 | Compounds and Uses Thereof | MAPT, BDNF, PYGB | MAPT 1/4885MEN1 890/4885KMT2A 1551/4885 |
| US-20090036454-A1 | Compounds and Uses Thereof | MAPT, BDNF, PYGB | MAPT 1/4885MEN1 890/4885KMT2A 1551/4885 |
| US-20100184738-A1 | Uses of cinnoline compounds to treat schizophrenia | COMT, BACE1, CHAT | MAPT 21/4885MEN1 720/4885KMT2A 3370/4885 |
| US-20080318925-A1 | Compounds and Uses Thereof - 849 | COMT, UGT1A9, BACE1 | MAPT 4/4885MEN1 3378/4885KMT2A 2812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.